Bristol-Myers Squibb inked a pair of deals to broaden its immuno-oncology efforts: It will partner with Incyte in testing the latter's drug candidate INCB24360 with its own PD-1 drug nivolumab.
written on 27.05.2014
Bristol-Myers scores 2 more immuno-oncology deals as ASCO approaches
